Pagina inicial
Continue Watching
Últimos vídeos
Últimos vídeos
Brightcove Home Latest Listing
Oncology
Oncology
Brightcove Cards Listing
Hematology
Hematology
Brightcove Cards Listing
Popular em MedEnrich
Popular em MedEnrich
Popular in Sem nome
Myelodysplastic Syndromes23m 43s
Desenvolvimento e Atualizações na Biologia das Mielodisplasias
Desenvolvimento e Atualizações na Biologia das Mielodisplasias (MDS)
síndromes mielodisplásicas
mds
avanços na biologia
terapias inovadoras
epidemiologia da mds
1
Desenvolvimento e Atualizações na Biologia das...
Oncospecials15m 30s
A Relevância dos Agentes TKI na era das imunoterapias para o tratamento do carcinoma de células Renais
ONCOPLUS apresenta: vídeo-aula com Dr. Denis Jardim na patologia de carcinoma de células renais.
oncologia
ccr
câncer renal
tki
sunitinibe
1
A Relevância dos Agentes TKI na era das...
Mieloma múltiplo9m 20s
Integrating Pomalidomide Based Regimens in Multiple Myeloma
Integrating pomalidomide and dexamethasone in the treatment of relapsed or refractory multiple myeloma (RRMM) involves using them as a core regimen, often combined with other agents like bortezomib or monoclonal antibodies for enhanced efficacy.
pomalidomide-dexamethasone
rrmm management
progression-free survival
combination therapies
1
Integrating Pomalidomide Based Regimens in Multiple...
Câncer de próstata6m 59s
Managing Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC)
3 randomized clinical trials (SPRATAN- Apalutamide), (PROSPER -Enzalutamide) & (ARAMIS -Darolutamide) have shown consistent and almost similar benefit in Metastasis Free Survival in nmCRPC
nmcrpc
metastasis free survival
spartan
prosper & aramis clinical trial
1
Managing Nonmetastatic Castration-Resistant...
Myelodysplastic Syndromes14m 13s
ASH 2022 Update on Myelodysplastic Syndromes
ASH 2022 - Update on Myelodysplastic Syndromes
low risk mds
venetoclax
viale -a
eln classification
low dose lenalidomide
tags: azacitidine
1
ASH 2022 Update on Myelodysplastic Syndromes
3m 56s
Duration of trastuzumab in patients with Her2 positive Metastatic Breast Cancer in prolonged remission
There are no randomized clinical trials addressing the continued use of Trastuzumab for Her2 positive MBC patients in prolonged remission and has become important and relevant clinical question.
her2 positive mbc
prolonged remission
trastuzumab duration
1
Duration of trastuzumab in patients with Her2...
Mieloma múltiplo17m 14s
Tratamento do mieloma múltiplo
Tratamento do mieloma multiplo_Dr Ederson Mattos
mm
mieloma múltiplo
tratamento
lenalidomida
nccn
ederson mattos
1
Tratamento do mieloma múltiplo
Acute Myeloid Leukaemia12m 22s
EHA 2022 Updates : AML
EHA Updates AML : QuANTUM phase 3 study showed significant overall survival in adults having FLT3-ITD+ acute myeloid leukaemia with addition of quizartinib to standard induction and consolidation therapy alone.
aml
decitabine
g-csf
hypomethylating agents
1
EHA 2022 Updates : AML
3m 56s
Duration of trastuzumab in patients with Her2 positive Metastatic Breast Cancer in prolonged remission
There are no randomized clinical trials addressing the continued use of Trastuzumab for Her2 positive MBC patients in prolonged remission and has become important and relevant clinical question.
her2 positive mbc
prolonged remission
trastuzumab duration
1
Duration of trastuzumab in patients with Her2...
11m 28s
ESR1 Mutation in Hormone Receptor Positive Advanced Breast Cancer
ESR1 mutation leads to ligand independent activation of estrogen receptor. ESR1 mutations were first described in 1997 & their role remain underestimated as initial research was focused on primary tumor wherein these mutations were absent.
aromatase inhibitor resistance
hr +ve mbc
esr1 mutation
fulvestrant
1